Table 3.

Patient characteristics

HGBCL (n = 22)BL (n = 46)
Median age (range) 55 (26-77) 45 (21-69) 
Gender - males 15 (68%) 37 (80%) 
ECOG-PS >1 8 (36%) 18 (39%) 
HIV seropositivity 9 (41%) 37 (80%) 
HBV or HCV seropositivity 4 (18%) 15 (33%) 
B symptoms 8 (36%) 20 (43%) 
IPI ≥2 18 (82%) 38 (83%) 
Burkitt lymphoma IPI score ≥2  NA 25 (54%) 
High LDH serum level 18 (82%) 37 (80%) 
Stage (Ann Arbor) III-IV 20 (91%) 40 (87%) 
Extranodal disease 18 (82%) 32 (70%) 
CNS involvement  1 (4%) 8 (17%) 
Bone marrow infiltration 2 (9%) 11 (24%) 
Bulky disease  11 (50%) 22 (48%) 
Single hit (FISH; MYC12 (54%) 46 (100%) 
Double hit (MYC + BCL2 or BCL69 (41%) — 
Triple hit (MYC + BCL2 + BCL61 (4%) — 
HGBCL (n = 22)BL (n = 46)
Median age (range) 55 (26-77) 45 (21-69) 
Gender - males 15 (68%) 37 (80%) 
ECOG-PS >1 8 (36%) 18 (39%) 
HIV seropositivity 9 (41%) 37 (80%) 
HBV or HCV seropositivity 4 (18%) 15 (33%) 
B symptoms 8 (36%) 20 (43%) 
IPI ≥2 18 (82%) 38 (83%) 
Burkitt lymphoma IPI score ≥2  NA 25 (54%) 
High LDH serum level 18 (82%) 37 (80%) 
Stage (Ann Arbor) III-IV 20 (91%) 40 (87%) 
Extranodal disease 18 (82%) 32 (70%) 
CNS involvement  1 (4%) 8 (17%) 
Bone marrow infiltration 2 (9%) 11 (24%) 
Bulky disease  11 (50%) 22 (48%) 
Single hit (FISH; MYC12 (54%) 46 (100%) 
Double hit (MYC + BCL2 or BCL69 (41%) — 
Triple hit (MYC + BCL2 + BCL61 (4%) — 

ECOG-PS, ECOG performance status score; NA, not applicable.

Burkitt Lymphoma IPI (BL-IPI) includes age ≥40 years old, ECOG-PS >1, serum LDH >3 times upper limit of normal, and CNS involvement.21 

Only patients with meningeal disease were considered, whereas patients with intraparenchymal brain lesions were excluded.

Bulky disease was defined by a lesion with the largest diameter of 10 cm or more.

or Create an Account

Close Modal
Close Modal